Regeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including mā¦ read more
Healthcare
Biotechnology
35 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$618.95
Price+2.66%
$16.03
1Y
Price
Market Cap
$63.765b
Large
Price/Earnings 3y Avg5y Avg
15.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+26.8%
EBITDA Margin+20.2%
Net Profit Margin+23.5%
Free Cash Flow Margin+26.8%
EBITDA Margin+20.2%
Net Profit Margin+23.5%
Free Cash Flow MarginRevenue
$14.920b
+4.0%
1y CAGR+4.4%
3y CAGR+5.3%
5y CAGREarnings
$4.423b
-1.8%
1y CAGR+4.0%
3y CAGR+0.8%
5y CAGREPS
$41.04
-1.1%
1y CAGR+5.8%
3y CAGR+2.1%
5y CAGRBook Value
$31.424b
$40.869b
Assets$9.445b
Liabilities$2.706b
DebtDebt to Assets
6.6%
0.5x
Debt to EBITDAFree Cash Flow
$4.155b
+1.8%
1y CAGR+4.4%
3y CAGR-1.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company